Columns: General -- Sales -- Acquisition -- WAC
| OSHPD ID | Manufacturer Name | Date Reported | Description | Acquisition Date | Acquired From | Acquisition Price | Price Comment |
|---|---|---|---|---|---|---|---|
| Accord BioPharma, Inc. | Hercessi Intravenous Solution Reconstituted 150 MG | ||||||
| Accord BioPharma, Inc. | Hercessi Intravenous Solution Reconstituted 420 MG | ||||||
| Akebia Therapeutics, Inc. | VAFSEO TABLETS 1 PACK 60 TABS 150 MG | ||||||
| Akebia Therapeutics, Inc. | VAFSEO TABLETS 1 PACK 60 TABS 300 MG | ||||||
| Amneal Pharmaceuticals | Everolimus Tablets for Oral Suspension 2mg | ||||||
| Amneal Pharmaceuticals | Everolimus Tablets for Oral Suspension 3mg | ||||||
| Amneal Pharmaceuticals | Everolimus Tablets for Oral Suspension 5mg | ||||||
| Amneal Pharmaceuticals | Mesalamine Delayed-Release Tablets 800mg 180 ct | ||||||
| Amneal Pharmaceuticals | Methylene Blue Injection, USP 50mg/10mL | ||||||
| ANIP | INZIRQO - Powder, For Suspension - 10mg/ml - 80ml in 1 bottle | ||||||
| Astellas Pharma US, Inc. | VYLOY® (zolbetuximab - clzb) 300mg vial | ||||||
| Aurobindo Pharma USA, Inc. | Pazopanib Tablets | ||||||
| Aurobindo Pharma USA, Inc. | Rivaroxaban 2.5mg tablets - 180s | ||||||
| AvKare | Sunitinib Malate 37.5mg Capsule 28ct | ||||||
| Avyxa Pharma, LLC | AXTLE (pemetrexed) Injection 100 mg/vial, SDV | 2024-07-01 |
|
||||
| Avyxa Pharma, LLC | AXTLE (pemetrexed) Injection 500 mg/vial, SDV | 2024-07-01 |
|
||||
| Biocon Biologics Inc. | Yesintek 130 mg/26 mL (5 mg/mL) injection in an SDV | ||||||
| Biocon Biologics Inc. | Yesintek 45 mg/0.5 mL injection in a single-dose prefilled syringe | ||||||
| Biocon Biologics Inc. | Yesintek 45 mg/0.5 mL injection in an SDV | ||||||
| Biocon Biologics Inc. | Yesintek 90 mg/mL injection in a single-dose prefilled syringe | ||||||
| Biocon Limited | Dasatinib Tablets 100mg 30ct | ||||||
| Biocon Limited | Dasatinib Tablets 140mg 30ct | ||||||
| Biocon Limited | Dasatinib Tablets 20mg 60ct | ||||||
| Biocon Limited | Dasatinib Tablets 50mg 60ct | ||||||
| Biocon Limited | Dasatinib Tablets 70mg 60ct | ||||||
| Biocon Limited | Dasatinib Tablets 80mg 30ct | ||||||
| Breckenridge Pharmaceutical | EVEROLIMUS TFOS 2MG 4X7 | ||||||
| Breckenridge Pharmaceutical | EVEROLIMUS TFOS 3MG 4X7 | ||||||
| Breckenridge Pharmaceutical | EVEROLIMUS TFOS 5MG 4X7 | ||||||
| Bristol Myers Squibb | Opdivo Qvantig 600 mg-10,000 unit/5mL (VIAL (ML)) | ||||||
| Carnegie Pharmaceuticals LLC | E.E.S. 400 ORAL TABLET 400 MG | 2024-11-11 |
|
The acquisition price is inclusive of all EES products on this submission and other erythromycin products not launched yet. | |||
| Carnegie Pharmaceuticals LLC | E.E.S. GRANULES ORAL SUSPENSION RECONSTITUTED 200 MG/5ML 100ML | 2024-11-11 |
|
The acquisition price is inclusive of all EES products on this submission and other erythromycin products not launched yet. | |||
| Carnegie Pharmaceuticals LLC | E.E.S. GRANULES ORAL SUSPENSION RECONSTITUTED 200 MG/5ML 200ML | 2024-11-11 |
|
The acquisition price is inclusive of all EES products on this submission and other erythromycin products not launched yet. | |||
| Carnegie Pharmaceuticals LLC | ERYPED 400 ORAL SUSPENSION RECONSTITUTED 400 MG/5ML 30 TABLETS | 2024-11-11 |
|
The acquisition price is inclusive of all EES products on this submission and other erythromycin products not launched yet. | |||
| Celltrion USA, Inc. | STEQEYMA 130MG/26ML (5mg/mL) Injectable; Subcutaneous Vial | ||||||
| Celltrion USA, Inc. | STEQEYMA 45MG/0.5ML Injectable; Subcutaneous Single-dose prefilled syringe with safety guard | ||||||
| Celltrion USA, Inc. | STEQEYMA 90MG/ML Injectable; Subcutaneous Single-dose prefilled syringe with safety guard | ||||||
| Celltrion USA, Inc. | ADALIMUMAB-AATY STARTER PACK 80 mg/0.8 ml | ||||||
| Chartwell Rx LLC | Promethazine HCL Oral Solution 6.25mg/5mL 20 x 10mL UD | 2023-06-28 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Promethazine HCL Oral Solution 6.25mg/5mL 20 x 5mL UD | 2023-06-28 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Lacosamide Oral Solution USP C-V 10mg/ml 20x10UD | 2023-09-21 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Lacosamide Oral Solution USP C-V 10mg/ml 20x5UD | 2023-09-21 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Memantine HCl Oral Solution 2MG/ML 20x5ML UD | 2022-09-22 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Acyclovir (Base) 200MG/5ML 20x20ML UD | 2023-08-04 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Acyclovir (Base) 200MG/5ML 20x5ML UD | 2023-08-04 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Albuterol (Sulfate) DAA Syrup Regular 2MG/5ML 20x20ML UD | 2020-11-25 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Albuterol (Sulfate) DAA Syrup Regular 2MG/5ML 20x5ML UD | 2020-11-25 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Lamivudine Oral Solution 10MG/ML 20x30ML UD | 2023-06-22 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Citalopram (Hydrobromide) 10MG/5ML 20x10ML UD | 2022-09-21 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Escitalopram Oxalate Oral Solution 5 MG/5ML 20x10ML UD | 2023-06-22 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Oxybutynin Chloride Solution 5 MG/5ML 20x5ML UD | 2022-03-24 |
|
Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Section 10. ANDA was acquired as part of a bulk transaction for multiple ANDAs and no specific cost or value can be assigned to this particular ANDA. | |||
| Chartwell Rx LLC | Phenobarbital Elixir 20MG/5ML 20x15ML UD | ||||||
| Chartwell Rx LLC | Phenobarbital Elixir 20MG/5ML 20x5ML UD | ||||||
| Chartwell Rx LLC | Phenobarbital Elixir 20MG/5ML 20x7.5ML UD | ||||||
| Chartwell Rx LLC | Tricitrates (Potassium Salt, Sodium Salt, Citric Acid) 550-500-334MG/5ML 20x5ML UD | ||||||
| Cintex Services LLC | ERGOTAMINE TARTRATE AND CAFFEINE (CAFFEINE; ERGOTAMINE TARTRATE) 100MG;1MG Oral Tablet, 40ct Bottle [Qty: 1] | ||||||
| Daiichi Sankyo, Inc. | "DATROWAY® (datopotamab deruxtecan-dlnk) One 100 mg single-dose vial" | ||||||
| Deciphera Pharmaceuticals, LLC | Romvimza (vimseltinib) Capsule, 30 mg 1 Carton (8 count blister in wallet) | ||||||
| Dr. Reddy's Laboratories, Inc. | Dasatinib 100mg Tablet, 30 | ||||||
| Dr. Reddy's Laboratories, Inc. | Dasatinib 140mg Tablet, 30 | ||||||
| Dr. Reddy's Laboratories, Inc. | Dasatinib 20mg Tablet, 60 | ||||||
| Dr. Reddy's Laboratories, Inc. | Dasatinib 50mg Tablet, 60 | ||||||
| Dr. Reddy's Laboratories, Inc. | Dasatinib 70mg Tablet, 60 | ||||||
| Dr. Reddy's Laboratories, Inc. | Dasatinib 80mg Tablet, 30 | ||||||
| Fresenius Kabi USA LLC | Calcitonin Salmon Injection Solution Package Size 2ml Package Quantity 1 | ||||||
| Fresenius Kabi USA LLC | Otulfi® (ustekinumab-aauz) 130mg/26mL Vial for intravenous infusion Package Quantity 1 | ||||||
| Fresenius Kabi USA LLC | Otulfi® (ustekinumab-aauz) 45mg/0.5 mL Prefilled Syringes Package Quantity 1 | ||||||
| Fresenius Kabi USA LLC | Otulfi® (ustekinumab-aauz) 90mg/1mL Prefilled Syringes Package Quantity 1 | ||||||
| Genentech USA | Evrysdi 5mg Tablets 30 Tablets | ||||||
| Glenmark Pharmaceuticals Inc., USA | Phytonadione Injectable Emulsion 10 mg/mL 25 Vials | ||||||
| Hikma Pharmaceuticals USA Inc | Mercaptopurine Oral Suspension, 20mg/mL, 100 mL Bottle | ||||||
| INA Pharmaceutics Inc | Gabarone (Gabapentin) 100MG, 90 ct tabs | ||||||
| INA Pharmaceutics Inc | Gabarone (Gabapentin) 400MG, 90 ct tabs | ||||||
| Incyte Corporation | Niktimvo (axatilimab-csfr) injection 22mg/0.44mL, for intravenous use, 1 vial | 2021-09-27 | 152000000.0000 | Terms of the Collaboration: Under the terms of the agreement, Incyte will lead global commercial activities for axatilimab across all indications. The companies will participate in a 50:50 profit share in the U.S., and Syndax will receive double-digit royalties on sales outside of the U.S. Syndax will retain the option to co-promote axatilimab for any approved indications in the U.S. In connection with the agreement, Syndax will receive an upfront payment of $117 million plus a $35 million equity investment, which will be purchased at $24.62 per share, a 30% premium to the volume weighted average price over the 10 days prior to September 24, 2021. Syndax will also be eligible to receive up to an additional $450 million in potential regulatory, development and commercial milestone payments. The companies will share development costs associated with global and U.S.-specific trials for all agreed upon trials at a rate of 55% (Incyte) and 45% (Syndax), with Incyte responsible for 100% of future development costs for trials that are specific to ex-U.S. countries. Syndax will fund the initial development of axatilimab in IPF and Incyte will have the option to co-fund late-stage development for this indication. | |||
| Incyte Corporation | Niktimvo (axatilimab-csfr) injection 9mg/0.18mL, for intravenous use, 1 Vial | 2021-09-27 | 152000000.0000 | Terms of the Collaboration: Under the terms of the agreement, Incyte will lead global commercial activities for axatilimab across all indications. The companies will participate in a 50:50 profit share in the U.S., and Syndax will receive double-digit royalties on sales outside of the U.S. Syndax will retain the option to co-promote axatilimab for any approved indications in the U.S. In connection with the agreement, Syndax will receive an upfront payment of $117 million plus a $35 million equity investment, which will be purchased at $24.62 per share, a 30% premium to the volume weighted average price over the 10 days prior to September 24, 2021. Syndax will also be eligible to receive up to an additional $450 million in potential regulatory, development and commercial milestone payments. The companies will share development costs associated with global and U.S.-specific trials for all agreed upon trials at a rate of 55% (Incyte) and 45% (Syndax), with Incyte responsible for 100% of future development costs for trials that are specific to ex-U.S. countries. Syndax will fund the initial development of axatilimab in IPF and Incyte will have the option to co-fund late-stage development for this indication. | |||
| Ingenus Pharmaceuticals, LLC | Fentanyl 50mcg/hr Transdermal Patch | ||||||
| Ingenus Pharmaceuticals, LLC | Fentanyl 75mcg/hr Transdermal Patch | ||||||
| Ingenus Pharmaceuticals, LLC | Fentanyl 100mcg/hr Transdermal Patch | ||||||
| Ingenus Pharmaceuticals, LLC | Fentanyl 25mcg/hr Transdermal Patch | ||||||
| Ingenus Pharmaceuticals, LLC | Fentanyl 12mcg/hr. Transdermal Patch | ||||||
| Ingenus Pharmaceuticals, LLC | Fentanyl 37.5mcg/hr Transdermal Patch | ||||||
| Ingenus Pharmaceuticals, LLC | Fentanyl Transdermal Patch 62.5mcg/hr. | ||||||
| Ingenus Pharmaceuticals, LLC | Fentanyl Transdermal Patch 87.5mcg/hr. | ||||||
| Lumicell | Lumisight Intravenous Solution Reconstituted 39 MG, 1 Each, Unit-Dose, Vial Qty 10 | ||||||
| Medexus Pharma, Inc | GRAFAPEX (treosulfan) for injection 5g/vial | ||||||
| Merck Sharp & Dohme LLC | PREVYMIS 120 mg/packet oral pellets 30 packets | ||||||
| Merck Sharp & Dohme LLC | PREVYMIS 20 mg/packet pellets 30 packets | ||||||
| Mesoblast Inc. | Ryoncil (remestemcel-l-rknd) 1 Kit (1 Single Use Vial) Target 25 X 10^6 MSCs/ 3.8mL (6.68 x 10^6 MSCs/mL) for resuspension and infusion | ||||||
| Mesoblast Inc. | Ryoncil (remestemcel-l-rknd) 1 Kit (2 Single Use Vials) Target 25 X 10^6 MSCs/ 3.8mL (6.68 x 10^6 MSCs/mL) for resuspension and infusion | ||||||
| Mesoblast Inc. | Ryoncil (remestemcel-l-rknd) 1 Kit (3 Single Use Vials) Target 25 X 10^6 MSCs/ 3.8mL (6.68 x 10^6 MSCs/mL) for resuspension and infusion | ||||||
| Mesoblast Inc. | Ryoncil (remestemcel-l-rknd) 1 Kit (4 Single Use Vials) Target 25 X 10^6 MSCs/ 3.8mL (6.68 x 10^6 MSCs/mL) for resuspension and infusion | ||||||
| Mesoblast Inc. | Ryoncil (remestemcel-l-rknd) 1 Kit (5 Single Use Vials) Target 25 X 10^6 MSCs/ 3.8mL (6.68 x 10^6 MSCs/mL) for resuspension and infusion | ||||||
| Mesoblast Inc. | Ryoncil (remestemcel-l-rknd) 1 Kit (6 Single Use Vials) Target 25 X 10^6 MSCs/ 3.8mL (6.68 x 10^6 MSCs/mL) for resuspension and infusion | ||||||
| Mesoblast Inc. | Ryoncil (remestemcel-l-rknd) 1 Kit (7 Single Use Vials) Target 25 X 10^6 MSCs/ 3.8mL (6.68 x 10^6 MSCs/mL) for resuspension and infusion | ||||||
| Mesoblast Inc. | Ryoncil (remestemcel-l-rknd) 1 Kit (8 Single Use Vials) Target 25 X 10^6 MSCs/ 3.8mL (6.68 x 10^6 MSCs/mL) for resuspension and infusion | ||||||
| Mylan Pharmaceuticals Inc | Ferric Citrate 210mg | ||||||
| Neurelis | Valtoco 10 MG Dose Nasal Liquid 10 MG/0.1ML 5 per box | ||||||
| Neurelis | Valtoco 15 MG Dose Nasal Liquid Therapy Pack 2 x 7.5 MG/0.1ML 5 per box | ||||||
| Neurelis | Valtoco 20 MG Dose Nasal Liquid Therapy Pack 2 x 10 MG/0.1ML 5 per box | ||||||
| Neurelis | Valtoco 5 MG Dose Nasal Liquid 5 MG/0.1ML 5 per box | ||||||
| Neurotech Pharmaceuticals, Inc. | ENCELTO (revakinagene taroretcel-lwey, 82958-501-01), a single-dose implant that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing rhCNTF for intravitreal surgical placement. Opaque semi-permeable capsule. | ||||||
| Novo | ALHEMO (concizumab-mtci) injection 150 mg/1.5 mL (100 mg/mL); 1.5 mL in 1 prefilled pen | ||||||
| Novo | ALHEMO (concizumab-mtci) injection 60 mg/1.5 mL (40 mg/mL); 1.5 mL in 1 prefilled pen | ||||||
| Novo | ALHEMO (concizumab-mtci) injection 300 mg/3 mL (100 mg/mL); 3 mL in 1 prefilled pen | ||||||
| Nuvaila US, LLC | AMJEVITA 20mg/0.2ml PREFILLED SYRINGE 1 Count | 2024-07-08 |
|
Amjevita is manufactured pursuant to a private label distribution agreement executed on July 8, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | AMJEVITA 40mg/0.4ml AUTOINJECTOR 2 Count | 2024-07-08 |
|
Amjevita is manufactured pursuant to a private label distribution agreement executed on July 8, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | AMJEVITA 40mg/0.4ml PREFILLED SYRINGE 2 Count | 2024-07-08 |
|
Amjevita is manufactured pursuant to a private label distribution agreement executed on July 8, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | AMJEVITA 80mg/0.8ml AUTOINJECTOR 2 Count | 2024-07-08 |
|
Amjevita is manufactured pursuant to a private label distribution agreement executed on July 8, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | WEZLANA 130mg/26ml SINGLE DOSE VIAL 1 Count | 2024-07-29 |
|
Wezlana is manufactured pursuant to a private label distribution agreement executed on July 29, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | WEZLANA 45mg/0.5ml PREFILLED SYRINGE 1 Count | 2024-07-29 |
|
Wezlana is manufactured pursuant to a private label distribution agreement executed on July 29, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | WEZLANA 45mg/0.5ml PREFILLED SYRINGE 1 Count Standard | 2024-07-29 |
|
Wezlana is manufactured pursuant to a private label distribution agreement executed on July 29, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | WEZLANA 45mg/0.5ml SINGLE DOSE VIAL 1 Count | 2024-07-29 |
|
Wezlana is manufactured pursuant to a private label distribution agreement executed on July 29, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | WEZLANA 45mg/0.5ml SINGLE DOSE VIAL 1 Count Standard | 2024-07-29 |
|
Wezlana is manufactured pursuant to a private label distribution agreement executed on July 29, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | WEZLANA 90mg/ml PREFILLED SYRINGE 1 Count | 2024-07-29 |
|
Wezlana is manufactured pursuant to a private label distribution agreement executed on July 29, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| Nuvaila US, LLC | WEZLANA 90mg/ml PREFILLED SYRINGE 1 Count Standard | 2024-07-29 |
|
Wezlana is manufactured pursuant to a private label distribution agreement executed on July 29, 2024. The terms of the agreement are considered trade secrets and/or not otherwise in the public domain or publicly available. | |||
| PureTek Corporation | VennGel II, Diclofenac Sodium 1% Topical Gel (100gm), Alcohol Pads, Large, 100ct box | ||||||
| PureTek Corporation | Fungizyl AL, Dimethyl Sulfoxide 2%, Miconazole Nitrate 2%(1fl oz) | ||||||
| PureTek Corporation | Flotrex chewable multivitamins with 0.25mg Fluoride, Vitamin A (as Retinyl Acetate) 750 mcg RAE Vitamin C , Vitamin D3, Vitamin E, Thiamin , Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, 30ct | ||||||
| Sagent Pharmaceuticals | Isoproterenol Hydrochloride Injection (0.2mg/ml, 1ml, 10x1ml) | ||||||
| Sagent Pharmaceuticals | Isoproterenol Hydrochloride Injection (0.2mg/ml, 5ml, 10x5ml) | ||||||
| Sagent Pharmaceuticals | Procainamide Hydrochloride Injection (500mg/ml, 2ml, 10x2ml) | ||||||
| Sandoz Inc. | ADALIMUMAB 80MG/0.8ML 2LISY PE BI V1 US | ||||||
| Sandoz Inc. | Edaravone 30MG/100ML 2LIBA US | ||||||
| Sandoz Inc. | PYZCHIVA 130MG/26ML 26ML LIVI US | ||||||
| Sandoz Inc. | PYZCHIVA 45MG/0.5ML 0.5ML LISY US | ||||||
| Sandoz Inc. | PYZCHIVA 90MG/1ML 1ML LISY US | ||||||
| Solubiomix LLC | Ultramicrosize Griseofulvin, 165 mg, tablet, 30 count | ||||||
| SpringWorks Therapeutics | Gomekli (mirdametinib) 1mg Capsules, 42-ct bottle | 2017-08-18 | 229800000.0000 | In August 2017, SpringWorks entered into a license agreement with Pfizer, pursuant to which we acquired exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture and commercialize mirdametinib for the treatment of all diseases. Pursuant to the license agreement, SpringWorks is required to pay Pfizer up to an aggregate of $229.8 million upon achievement of certain commercial milestone events, and will pay Pfizer tiered royalties on sales of mirdametinib at percentages ranging from the mid-single digits to the low 20s, that may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition | |||
| SpringWorks Therapeutics | Gomekli (mirdametinib) 1mg tablets, 42-ct bottle | 2017-08-18 | 229800000.0000 | In August 2017, SpringWorks entered into a license agreement with Pfizer, pursuant to which we acquired exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture and commercialize mirdametinib for the treatment of all diseases. Pursuant to the license agreement, SpringWorks is required to pay Pfizer up to an aggregate of $229.8 million upon achievement of certain commercial milestone events, and will pay Pfizer tiered royalties on sales of mirdametinib at percentages ranging from the mid-single digits to the low 20s, that may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition | |||
| SpringWorks Therapeutics | Gomekli (mirdametinib) 1mg tablets, 84-ct bottle | 2017-08-18 | 229800000.0000 | In August 2017, SpringWorks entered into a license agreement with Pfizer, pursuant to which we acquired exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture and commercialize mirdametinib for the treatment of all diseases. Pursuant to the license agreement, SpringWorks is required to pay Pfizer up to an aggregate of $229.8 million upon achievement of certain commercial milestone events, and will pay Pfizer tiered royalties on sales of mirdametinib at percentages ranging from the mid-single digits to the low 20s, that may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition | |||
| SpringWorks Therapeutics | Gomekli (mirdametinib) 2mg Capsules, 42-ct bottle | 2017-08-18 | 229800000.0000 | In August 2017, SpringWorks entered into a license agreement with Pfizer, pursuant to which we acquired exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture and commercialize mirdametinib for the treatment of all diseases. Pursuant to the license agreement, SpringWorks is required to pay Pfizer up to an aggregate of $229.8 million upon achievement of certain commercial milestone events, and will pay Pfizer tiered royalties on sales of mirdametinib at percentages ranging from the mid-single digits to the low 20s, that may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition | |||
| SpringWorks Therapeutics | Gomekli (mirdametinib) 2mg Capsules, 84-ct bottle | 2017-08-18 | 229800000.0000 | In August 2017, SpringWorks entered into a license agreement with Pfizer, pursuant to which we acquired exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture and commercialize mirdametinib for the treatment of all diseases. Pursuant to the license agreement, SpringWorks is required to pay Pfizer up to an aggregate of $229.8 million upon achievement of certain commercial milestone events, and will pay Pfizer tiered royalties on sales of mirdametinib at percentages ranging from the mid-single digits to the low 20s, that may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition | |||
| Stallergenes Greer USA | PALFORZIA - Each package contains 13 capsules: (Level A) One 0.5 mg capsule (Level B) One 1 mg capsule (Level C) One 0.5 mg capsule; One 1 mg capsule (Level D) Three 1 mg capsules (Level E) Six 1 mg capsules | ||||||
| Stallergenes Greer USA | PALFORZIA - Each package contains fifteen 1mg capsules | ||||||
| SUN PHARMACEUTICALS | Deflazacort Oral Tablets 6mg, 100ct | ||||||
| SUN PHARMACEUTICALS | Deflazacort Oral Tablets, 18mg, 30ct | ||||||
| SUN PHARMACEUTICALS | Deflazacort Oral Tablets, 30mg, 30ct | ||||||
| SUN PHARMACEUTICALS | Deflazacort Oral Tablets, 36mg, 30ct | ||||||
| Syndax Pharmaceuticals, Inc. | REVUFORJ (revumenib) 25mg Package Quantity 30 Tablets | ||||||
| Teva Pharmaceuticals USA | Simlandi Pre-Filled Syringe Kit 80mg/0.8mL | ||||||
| Teva Pharmaceuticals USA | Simlandi (2 syringe) Pre-Filled Syringe Kit 20mg/0.2mL | ||||||
| Teva Pharmaceuticals USA | SELARSDI Prefilled Syringe 45 mg/0.5 mL | ||||||
| Teva Pharmaceuticals USA | SELARSDI Prefilled Syringe 90 mg/mL | ||||||
| Teva Pharmaceuticals USA | OCTREOTIDE ACETATE INJ 10MG/VIAL KIT 1 | ||||||
| Teva Pharmaceuticals USA | SELARSDI Single Dose Vial 130mg/26mL | ||||||
| Tilde Sciences LLC | Vecamyl Oral Tablet 2.5 MG, 100 count bottle | 2023-09-22 | 650000.0000 | Drug was acquired with another asset in a bankruptcy. Price provided is inclusive of the other asset. Company was required to relabel drug prior to disribution. | |||
| Upsher-Smith Laboratories, LLC | Deflazacort 18mg tblt Btl 30ct | ||||||
| Upsher-Smith Laboratories, LLC | Deflazacort 30mg tblt Btl 30ct | ||||||
| Upsher-Smith Laboratories, LLC | Deflazacort 36mg tblt Btl 30ct | ||||||
| Upsher-Smith Laboratories, LLC | Deflazacort 6mg tblt Btl 100ct | ||||||
| Validus Pharmaceuticals | Trazodone Hydrochloride Oral Solution, 10mg/mL Raldesy TM 150ml HDPE Bottle Pack | ||||||
| Validus Pharmaceuticals | Trazodone Hydrochloride Oral Solution, 10mg/mL Raldesy TM 300ml HDPE Bottle Pack | ||||||
| Verrica Pharmaceuticals Inc. | YCANTH 0.7% (w/v) 1 applicator | ||||||
| Vertex Pharmaceuticals Incorporated | ALYFTREK (vanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg film-coated tablets) is supplied as a 56-count tablet carton (4 wallets, each wallet containing 14 tablets of vanzacaftor/tezacaftor/deutivacaftor). | ||||||
| Vertex Pharmaceuticals Incorporated | ALYFTREK (vanzacaftor 4 mg/tezacaftor 20 mg/deutivacaftor 50 mg film-coated tablets) is supplied as a 84-count tablet carton (4 wallets, each wallet containing 21 tablets of vanzacaftor/tezacaftor/deutivacaftor) | ||||||
| XGen Pharmaceuticals DJB | Nelarabine Injection 250mg/50mL Vial | ||||||
| XGen Pharmaceuticals DJB | Nelarabine Injection 250mg/50mL x 6 | ||||||
| Zydus Pharmaceuticals (USA) Inc. | Beizray (Docet) Inj 80mg/4mL (160mg Kit) | ||||||
| Zydus Pharmaceuticals (USA) Inc. | Dasatinib 100mg Tablets 30 Count | ||||||
| Zydus Pharmaceuticals (USA) Inc. | Dasatinib 140mg Tablets 30 Count | ||||||
| Zydus Pharmaceuticals (USA) Inc. | Dasatinib 20mg Tablets 30 Count | ||||||
| Zydus Pharmaceuticals (USA) Inc. | Dasatinib 50mg Tablets 30 Count | ||||||
| Zydus Pharmaceuticals (USA) Inc. | Dasatinib 70mg Tablets 30 Count | ||||||
| Zydus Pharmaceuticals (USA) Inc. | Dasatinib 80mg Tablets 30 Count | ||||||
| None | None | ||||||
| None | None |